

King Saud University

Arabian Journal of Chemistry

www.ksu.edu.sa www.sciencedirect.com



ORIGINAL ARTICLE



Novel fluoroquinolone derivatives bearing N-thiomide linkage with 6-substituted-2aminobenzothiazoles: Synthesis and antibacterial evaluation

Prabodh Chander Sharma ^{a,*}, Ankit Jain ^b, Mohammad Shahar Yar ^c, Rakesh Pahwa ^a, Jasbir Singh ^d, Preeti Chanalia ^d

^a Institute of Pharmaceutical Sciences, Kurukshetra University, Kurukshetra 136 119, Haryana, India

^b Department of Pharmaceutical Chemistry, Rajendra Institute of Technology & Sciences, Sirsa 125 055, Haryana, India

^c Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Hamdard University, New Delhi 110 062, India

^d Department of Biochemistry, Kurukshetra University, Kurukshetra 136 119, Haryana, India

Received 6 August 2011; accepted 2 November 2012 Available online 16 November 2012

KEYWORDS

Fluoroquinolone; Antibacterial; Benzothiazole; Synthesis **Abstract** A series of novel fluoroquinolone derivatives bearing *N*-thiomide linkage with 6-substituted-2-aminobenzothiazole substituents at the C-7 position were synthesized to obtain potent analogs active against bacterial strains. Some compounds exhibited excellent antibacterial activity against *Staphylococcus auerus*, *Escherichia coli*, *Bacillus subtilis*, *Pseudomonas aeruginosa* bacterial strains. Among all the synthesized compounds 6-nitro substituted benzothiazole along with norflox-acin (**4b**) and gatifloxacin (**4l**) showed MIC 05 µg/ml when tested against *S. auerus*. Moreover, compounds **4d**, **4f** and **4l** showed superior MIC (15, 10, and 15 µg/ml respectively) against *B. subtilis*. The results of the present study reveal that the compounds have significant antibacterial potential and are suitable candidates for further exploration.

© 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).

1. Introduction

* Corresponding author. Mobile: +91 9416025460.

E-mail address: sharma_prabodh@rediffmail.com (P.C. Sharma).

 $^{^{\}scriptscriptstyle{\rm th}}$ Peer review under responsibility of King Saud University.



Since the introduction of fluoroquinolones in late 1970s, they have generated great excitement, opportunities and applications in the antibacterial chemotherapeutic world, as these agents potentially offer all the general attributes of ideal antibacterial agents. Over the last 15 years, researchers have attempted and proved these attributes as reality (Andriole, 1988; Sharma and Jain, 2008). Initially, great improvement in potency, spectrum and *in vivo* efficiency was achieved as a

http://dx.doi.org/10.1016/j.arabjc.2012.11.002

1878-5352 © 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).

result of intensive structural modifications. Further, the systematic and well defined structure-activity relationships were established which reveal the optimal groups for each position in terms of size, shape and electronic properties. Once the multitude of new quinolones reached advanced toxicology and clinical trials, it was realized that quinolones like all other agents, do show some undesirable side effects in human and the laboratory testings. Their adverse reactions and toxicological profiles have been reviewed extensively (Lv et al., 2012). The major concern has been the growing incidences of resistance especially to Staphylococci and Enterococci. Some of the side effects of quinolone antibacterials are unacceptable, for example, grepafloxacin withdrawn from the market, due to increased cases of heart problems in clinical findings. Similarly trovafloxacin was removed from the market due to liver toxicity (Graul et al., 1999). The current phase of quinolone design is aimed at reducing or eliminating these side effects and overcome the emerging resistance through additional synthetic manipulations while further enhancing or maintaining potency.

Synthesis and evaluation of over 10,000 quinolone derivatives resulted in extensive knowledge of the structure–activity relationship for many quinolone substituents. The most intensive structural variation has been carried out on amines at the 7-position (Foroumadi et al., 2006; Foroumadi et al., 2005), partially due to the ease of their aromatic substitution reactions. Piperazine, aminopyrrolidine and their substituted derivatives have been the most successfully employed side chains, as evidenced by the compounds currently in the market (Sharma et al., 2009; Sharma et al., 2010; Domagala et al., 1988; Chu et al., 1985). Originally, the newer fluoroquinolones arose with the development of 7- piperazinyl quinolones, such as norfloxacin 1, ciprofloxacin 2 and gatifloxacin 3 (Fig. 1). The site near the C-7 substituent is regarded as drug enzyme interaction domain (Foroumadi et al., 2005).

These facts motivated our concern to prepare C-7 substituents of quinolones. The piperazine moiety of fluoroquinolones possesses enough structural flexibility to allow product optimization. Thus, we anticipated that safer and superior antibacterial compounds can be developed by attaching an appropriate moiety through *N*-atom of the substituents at C-7 position. In this communication, we report the synthesis, characterization and antibacterial activity of a number of *N*-substituent piperazinyl quinolones by introducing specific substituents in the piperazine unit of 7-piperazinyl quinolones.



Figure 1 Some commercially available fluoroquinolones.

Keeping in view the diverse biological activity profile of 2amino-6-substituted benzothiazoles such as cytotoxic, antibacterial, fungicidal, analgesic, antiinflammatory, antioxidant activities and pharmacological interventions of quinolone derivatives such as antibacterial, antimycobacterial, antimalarial, antioxidant, analgesic and antiviral activities, (Chu et al., 1985; Senthilkumar et al., 2009; Javashree et al., 2009; El-Gazzar et al., 2009; Dinakaran et al., 2008; Winter et al., 2008; German et al., 2008; Jazayeri et al., 2009) clubbing of these scaffolds was considered to be of significant relevance. Moreover, due to our ongoing endeavors (Sharma et al., 2010, 2011; Kharb et al., 2011, 2011a, b) and research program on the design and synthesis of novel antimicrobial agents, a number of potent fluoroquinolone derivatives(Lv et al., 2012; Sharma and Jain, 2008; Sharma et al., 2011) have been synthesized. Recently, we have reported the synthesis of novel fluoroquinolone derivatives annulated with benzothiazoles with promising antibacterial activity (Sharma et al., 2011a, 2015). It was clearly indicated that clubbing of fluoroquinolone with benzothiazoles is worthwhile and the synthesized compounds were of promising pharmacological significance. Thus, the present study was aimed to achieve better antimicrobial profile at lower concentrations, by preparing N-substituted piperazinyl quinolone derivatives carrying benzothiazolyl substituents.

2. Experimental

2.1. General

All the chemicals and solvents used in this study were of laboratory grade and procured from E. Merck (Germany) and S. D. Fine Chemicals (India). Melting points were determined on a Labindia MR-VIS visual melting point apparatus and are uncorrected. The thin layer chromatography (TLC) plates (Silica Gel G) were used to confirm the purity of commercial reagents used, compounds synthesized and to monitor the reactions as well. Absorbance values against wavelength were taken on a Systronic double beam UV-166 spectrophotometer. The IR spectra were obtained on a Perkin Elmer IR spectrophotometer (KBr pellet). ¹H NMR spectra were recorded using Bruker 400 spectrometer and chemical shifts are expressed as δ (ppm) using tetramethylsilane as an internal standard in DMSO- d_6 . Mass spectra of some selected compounds were obtained using a micromass-Q-TOF-micro spectrometer.

2.2. Chemistry

2.2.1. General procedure for the synthesis of 2-amino-6substituted benzothiazole [26] (2a-2e)

The 2-amino-6-substituted benzothiazoles (2a–2e) were prepared by mixing p-substituted aniline (0.05 mol) (1a–1e) and potassium thiocyanate (0.2 mol) in 90 ml of 96% acetic acid. To this was added drop wise, with stirring, a solution of bromine (0.05 mol) in glacial acetic acid (37.5 ml) and temperature was maintained below 35 °C. After all the bromine solution was added, the mixture was stirred for another 10 h at room temperature and was filtered, the residue so obtained was washed with water. The combined filtrate and washings were neutralized with ammonium hydroxide solution. The precipitate thus obtained was collected and dried. Further purification was carried out by crystallization from benzene. Adopting the above procedure, five different 2-amino-6-substituted benzothiazoles (2a–2e) have been synthesized. The purity of the benzothiazoles was checked by TLC.

2.2.2. General procedure for the synthesis of fluoroquinolone derivatives (4a-4n)

For the synthesis of target fluoroquinolone derivatives, a mixture of 2-amino-6-substituted benzothiazole (0.05 mmol) (2a-2e), fluoroquinolone (0.05 mmol) (3a-3c) and carbon disulfide (0.05 mmol) in basic medium composed of sodium bicarbonate (NaHCO₃) (0.05 mmol) and N,N-dimethyl formamide (10 ml), was refluxed for 10 h. After complete consumption of fluoroquinolone in the reaction (monitored by thin layer chromatography), the reaction mixture was poured into ice cold water and the precipitate was filtered, washed with

water to yield the crude product. The precipitate was collected and dried. Further purification was carried out by crystallization from N,N-dimethyl formamide (DMF). The purity of title compounds was ascertained by thin layer chromatography. Employing the captioned procedure, fourteen novel target compounds (4a–4n) were synthesized. Structural and physicochemical data of synthesized compounds are presented in Table 1.

2.2.2.1. 1-Ethyl-6-fluoro-7-(4-(N-(6-methoxy-1,3-benzothiazol-2-yl)amino-1-thio-methyl)piperazin-1-yl)-1,4-dihydro-4-oxoquinoline-3-carboxylic acid (4a). M.p. 247–250 °C (67% yield). ¹H NMR (DMSO-d₆): δ /ppm = 1.38 (3H, J = 6.7, t, CH₃ ethyl), 2.49 (2H, J = 6.7, q, CH₂ ethyl), 3.02–3.76 (8H, m, piperazine), 3.93 (3H, s, OCH₃ benzothiazole), 6.76–7.93

Table 1Structural and physicochemical data of target compounds (4a-4n).								
		R		R^3 R^2				
Compound	\mathbf{R}^1	R ²	R ³	R	mp (°C)	Formula	Yield (%)	
4a 4b 4c 4d 4e 4f	-C ₂ H ₅ -C ₂ H ₅ -C ₂ H ₅ -C ₂ H ₅ -C ₂ H ₅	-H -H -H -H -H -H	-H -H -H -H -H -H	-OCH ₃ -NO ₂ -CH ₃ -F -Br -OCH ₃	247-250 278-281 254-257 245-248 256-259 326-329	$\begin{array}{c} C_{25}H_{24}FN_5O_4S_2\\ C_{24}H_{21}FN_6O_5S_2\\ C_{25}H_{24}FN_5O_3S_2\\ C_{24}H_{21}F_2N_5O_3S_2\\ C_{24}H_{21}BrFN_5O_3S_2\\ C_{26}H_{24}FN_5O_4S_2\\ \end{array}$	67 60 58 72 69 66	
4g	\neg	-H	H	-NO ₂	332–335	$C_{25}H_{21}FN_6O_5S_2$	64	
4h	$ \longrightarrow $	–H	H	-CH ₃	319–322	$C_{26}H_{24}FN_5O_3S_2$	59	
4i	$ \longrightarrow $	-H	H	–F	329–331	$C_{25}H_{21}F_2N_5O_3S_2\\$	64	
4j	$ \longrightarrow $	-H	H	-Br	327-330	$C_{25}H_{21}BrFN_5O_3S_2$	63	
4k	$ \longrightarrow $	-OCH ₃	-CH3	–OCH ₃	229–232	$C_{28}H_{28}FN_5O_5S_2$	68	
41	$ \longrightarrow $	-OCH ₃	-CH3	-NO ₂	199–202	$C_{27}H_{23}FN_6O_6S_2$	63	
4m	$ \longrightarrow $	-OCH ₃	-CH ₃	-CH ₃	197–200	$C_{28}H_{28}FN_5O_4S_2$	63	
4n	$ \rightarrow$	-OCH ₃	-CH ₃	–F	211–214	$C_{27}H_{25}F_2N_5O_4S_2$	64	

S571

{5H, m, Aromatic proton (H₅, H₈-quinolone and H₄', H₅', H₇benzothiazole)}, 8.90 (1H, s, H₂-quinolone), 9.36 (1H, s, NH), 15.14 (1H, s, COOH); IR (KBr): $cm^{-1} = 1585$ (C = C), 1705 (C = O), 1211 (C–O), 1157 (C–N), 3186–2854 (C–H), 3302 (COOH); MS: m/z = 541.6 (M⁺).

2.2.2.2. *I-Ethyl-6-fluoro-7-(4-(N-(6-nitro-1,3-benzothiazol-2-yl)amino-1-thio-methyl)piperazin-1-yl)-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid (4b)*. M.p. 278–281 °C (60% yield). ¹H NMR (DMSO-*d*₆): δ /*ppm* = 1.39 (3H, *J* = 7.2, t, CH₃ ethyl), 2.19 (2H, *J* = 7.2, q, CH₂ ethyl), 3.29–3.64 (8H, m, piperazine), 7.18–8.15 {5H, m, Aromatic proton (H₅, H₈-quinolone and H₄, H₅, H₇-benzothiazole)}, 8.63 (1H, s, H₂-quinolone), 9.35 (1H, s, NH), 15.24 (1H, s, COOH); IR (KBr): *cm* ⁻¹ = 1586 (C = C), 1718 (C = O), 1258 (C–O), 1052 (C–N), 2932 (C–H), 3415 (COOH); MS: *m*/*z* = 556.6 (M⁺).

2.2.2.3. 1-Ethyl-6-fluoro-7-(4-(N-(6-methyl-1,3-benzothiazol-2yl)amino-1-thio-methyl)piperazin-1-yl)-1,4-dihydro-4-oxoquinoline-3-carboxylic acid (4c). M.p. 254–257 °C (58% yield). ¹H NMR (DMSO- d_6): δ /ppm = 1.41 (3H, J = 6.6, t, CH₃ ethyl), 2.29–2.49 (2H, J = 6.6, q, CH₂ ethyl), 3.07–3.59 (8H, m, piperazine), 2.89 (3H, s, CH₃ benzothiazole), 6.98–7.93 {5H, m, Aromatic proton (H₅, H₈-quinolone and H₄, H₅, H₇-benzothiazole)}, 8.10 (1H, s, H₂ quinolone), 8.90 (1H, s, NH), 15.19 (1H, s, COOH); IR (KBr): $cm^{-1} = 1583$ (C = C), 1717 (C = O), 1262 (C-O), 1098 (C-N), 2922 (C-H), 3415 (COOH).

2.2.2.4. *1*-Ethyl-6-fluoro-7-(4-(*N*-(6-fluoro-1,3-benzothiazol-2yl)amino-1-thio-methyl)piperazin-1-yl)-1,4-dihydro-4-oxoquinoline-3-carboxylic acid (4d). M.p. 245–248 °C (72% yield). ¹H NMR (DMSO- d_6): δ /ppm = 1.37 (3H, J = 6.8, t, CH₃ ethyl), 1.89 (2H, J = 6.8, q, CH₂ ethyl), 3.31–4.28 (8H, m, piperazine), 6.97–8.10 {5H, m, Aromatic proton (H₅, H₈-quinolone and H₄, H₅, H₇-benzothiazole)}, 8.89 (1H, s, H₂-quinolone), 9.35 (1H, s, NH), 15.02 (1H, s, COOH); IR (KBr): cm ⁻¹ = 1586 (C = C), 1715 (C = O), 1255 (C–O), 1062 (C–N), 2933 (C–H), 3423 (COOH).

2.2.2.5. 7-(4-(N-(6-bromo-1,3-benzothiazol-2-yl)amino-1-thiomethyl)piperazin-1-yl)-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid (4e). M.p. 256–259 °C (69% yield). ¹H NMR (DMSO-d₆): δ /ppm = 1.38 (3H, J = 6.2, t, CH₃ ethyl), 1.89 (2H, J = 6.2, q, CH₂ ethyl), 2.95–3.93 (8H, m, piperazine), 7.17–8.10 {5H, m, Aromatic proton (H₅, H₈-quinolone and H₄, H₅', H₇-benzothiazole)}, 8.92 (1H, s, H₂-quinolone), 9.56 (1H, s, NH), 15.26 (1H, s, COOH); IR (KBr): cm ⁻¹ = 1585 (C = C), 1715 (C = O), 1227 (C–O), 1050 (C–N), 2932 (C–H), 3409 (COOH).

2.2.2.6. 1-Cyclopropyl-6-fluoro-7-(4-(N-(6-methoxy-1,3-benzothiazol-2-yl)amino-1-thio-methyl)piperazin-1-yl)-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid (4f). M.p. 326–329 °C (66% yield). ¹H NMR (DMSO- d_6): δ /ppm = 1.32 (4H, d, CH₂-CH₂- Cyclopropyl), 3.25 (1H, m, CH Cyclopropyl), 3.30–3.61 (8H, m, piperazine), 3.84 (3H, s, OCH₃ benzothiazole), 7.43–8.11 {5H, m, Aromatic proton (H₅, H₈-quinolone and H₄, H₅°, H₇-benzothiazole)}, 8.60 (1H, s, H₂-quinolone), 9.64 (1H, s, NH), 15.19 (1H, s, COOH); IR (KBr): cm ⁻¹ = 1581 (C = C), 1718 (C = O), 1257 (C-O), 1173 (C-N), 2924–2839 (C-H), 3294 (COOH). 2.2.2.7. 1-Cyclopropyl-6-fluoro-7-(4-(N-(6-nitro-1,3-benzothiazol-2-yl) amino-1-thio-methyl) piperazin-1-yl)-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid (4g). M.p. 332–335 °C (64% yield). ¹H NMR (DMSO-d₆): δ /ppm = 1.34 (4H, d, CH₂-CH₂- Cyclopropyl), 2.90 (1H, m, CH Cyclopropyl), 3.25–3.63 (8H, m, piperazine), 7.40–8.12 {5H, m, Aromatic proton (H₅, H₈-quinolone and H₄', H₅', H₇-benzothiazole)}, 8.23 (1H, s, H₂-quinolone), 9.09 (1H, s, NH), 14.87 (1H, s, COOH); IR (KBr): cm^{-1} = 1584 (C = C), 1715 (C = O), 1258 (C–O), 1062 (C-N), 2936 (C-H), 3448 (COOH); MS: m/z = 568.6 (M⁺).

2.2.2.8. *I-Cyclopropyl-6-fluoro-7-(4-(N-(6-methyl-1,3-ben-zothiazol-2-yl)amino-1-thio-methyl)piperazin-1-yl)-1,4-dihy-dro-4-oxo-quinoline-3-carboxylic acid (4h)*. M.p. 319–322 °C (59% yield). ¹H NMR (DMSO-*d*₆): δ /*ppm* = 1.18 (4H, d, CH₂-CH₂-Cyclopropyl), 2.87 (1H, m, CH Cyclopropyl), 3.33–3.80 (8H, m, piperazine), 2.49 (3H, s, CH₃ benzothiazole), 7.38–8.21 {5H, m, Aromatic proton (H₅, H₈-quinolone and H₄', H₅', H₇-benzothiazole)}, 8.65 (1H, s, H₂-quinolone), 9.34 (1H, s, NH), 15.12 (1H, s, COOH); IR (KBr): *cm* ⁻¹ = 1584 (C = C), 1718 (C = O), 1265 (C-O), 1203 (C-N), 3094–2839 (C-H), 3294 (COOH).

2.2.2.9. 1-Cyclopropyl-6-fluoro-7-(4-(N-(6-fluoro-1,3-benzothiazol-2-yl)amino-1-thio-methyl)piperazin-1-yl)-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid (4i). M.p. 329–331 °C (64% yield). ¹H NMR (DMSO- d_6): δ /ppm = 1.17 (4H, d, CH₂–CH₂–Cyclopropyl), 3.12 (1H, m, CH Cyclopropyl), 3.20–3.95 (8H, m, piperazine), 7.00–8.11 {5H, m, Aromatic proton (H₅, H₈-quinolone and H₄, H₅', H₇-benzothiazole)}, 8.64 (1H, s, H₂-quinolone), 9.29 (1H, s, NH), 15.09 (1H, s, COOH); IR (KBr): cm^{-1} = 1583 (C = C), 1717 (C = O), 1260 (C–O), 1057 (C–N), 2909 (C–H), 3416 (COOH).

2.2.2.10. 7-(4-(N-(6-bromo-1,3-benzothiazol-2-yl)amino-1thio-methyl)piperazin-1-yl)-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid (4j). M.p. 327–330 °C (63% yield). ¹H NMR (DMSO-d₆): δ /ppm = 1.16 (4H, d, CH₂-CH₂-Cyclopropyl), 3.02 (1H, m, CH Cyclopropyl), 3.28–3.80 (8H, m, piperazine), 7.19–8.11 {5H, m, Aromatic proton (H₅, H₈-quinolone and H₄·, H₅·, H₇-benzothiazole)}, 8.60 (1H, s, H₂-quinolone), 9.64 (1H, s, NH), 15.22 (1H, s, COOH); IR (KBr): cm^{-1} = 1585 (C = C), 1717 (C = O), 1260 (C–O), 1061 (C–N), 2917 (C–H), 3448 (COOH); MS: m/z = 602.5 (M⁺).

2.2.2.11. 1-Cyclopropyl-6-fluoro-8-methoxy-7-(4-(N-(6-methoxy-1,3-benzothiazol-2-yl) amino-1-thio-methyl)-3-methylpiperazin-1-yl)-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid (4k). M.p. 229–232 °C (68% yield). ¹H NMR (DMSO-d₆): δ /ppm = 1.27 (4H, d, CH₂–CH₂–Cyclopropyl), 2.82 (1H, m, CH Cyclopropyl), 3.26–3.66 (7H, m, piperazine), 3.87 (3H, s, OCH₃) 2.12–2.56 (3H, m, CH₃ piperazine), 6.90–8.28 {4H, m, Aromatic proton (H₅-quinolone and H₄, H₅, H₇-benzothiazole)}, 8.73 (1H, s, H₂-quinolone), 9.03 (1H, s, NH), 15.06 (1H, s, COOH); IR (KBr): cm^{-1} = 1585 (C = C), 1717 (C = O), 1254 (C–O), 1073 (C–N), 2917 (C–H), 3448 (COOH).

2.2.2.12. 1-Cyclopropyl-6-fluoro-8-methoxy-7-(3-methyl-4-(N-(6-nitro-1,3-benzothiazol-2-yl)amino-1-thio-methyl)piperazin-



 R^{3} = -H, -CH₃

Scheme 1 Synthetic route of target compounds.

1-yl)-*1*,4-*dihydro*-4-*oxo-quinoline-3-carboxylic acid (41)*. M.p. 199–202 °C (63% yield). ¹H NMR (DMSO-*d*₆): $\delta/ppm = 0.93$ (4H, d, CH₂–CH₂–Cyclopropyl), 3.15 (1H, m, CH Cyclopropyl), 3.28–3.85 (7H, m, piperazine), 2.18–2.65 (3H, m, CH₃ piperazine), 3.96 (3H, s, OCH₃), 7.16–8.00 {4H, m, Aromatic proton (H₅-quinolone and H₄·, H₅·, H₇·-benzothiazole)}, 8.44 (1H, s, H₂-quinolone), 9.76 (1H, s, NH), 15.35 (1H, s, COOH); IR (KBr): $cm^{-1} = 1586$ (C = C), 1718 (C = O), 1249 (C–O), 1064 (C–N), 2947 (C–H), 3421 (COOH).

2.2.2.13. 1-Cyclopropyl-6-fluoro-8-methoxy-7-(4-(N-(6-methyl-1,3-benzothiazol-2-yl)amino-1-thio-methyl)-3-methylpiperazin-1-yl)-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid (4m). M.p. 197–200 °C (63% yield). ¹H NMR (DMSO-d₆): δ /ppm = 1.22 (4H, d, CH₂-CH₂-Cyclopropyl), 2.92 (1H, m, CH Cyclopropyl), 3.04–3.76 (7H, m, piperazine), 2.19–2.76 (3H, m, CH₃ piperazine), 3.88 (3H, s, OCH₃), 7.02–8.20 {4H, m, Aromatic proton (H₅-quinolone and H₄, H₅, H₇-benzothiazole)}, 8.78 (1H, s, H₂-quinolone), 9.33 (1H, s, NH), 15.18 (1H, s, COOH); IR (KBr): $cm^{-1} = 1587$ (C = C), 1715 (C = O), 1268 (C–O), 1109 (C–N), 2917 (C–H), 3413 (COOH); MS: m/z = 581.7 (M⁺).

2.2.2.14. 1-Cyclopropyl-6-fluoro-7-(4-(N-(6-fluoro-1,3-benzothiazol-2-yl)amino-1-thio-methyl)-3-methylpiperazin-1-yl)-8methoxy-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid (4n). M.p. 211–214 °C (64% yield). ¹H NMR (DMSO-d₆): δ / ppm = 1.32 (4H, d, CH₂–CH₂–Cyclopropyl), 3.15 (1H, m, CH Cyclopropyl), 3.37–3.81 (7H, m, piperazine), 2.80–2.98 (3H, m, CH₃ piperazine), 3.94 (3H, s, OCH₃), 6.98–7.94 {4H, m, Aromatic proton (H₅-quinolone and H₄, H₅, H₇-benzothiazole)}, 8.67 (1H, s, H₂-quinolone), 9.28 (1H, s, NH), 15.17 (1H, s, COOH); IR (KBr): cm^{-1} = 1583 (C = C), 1705 (C = O), 1265 (C–O), 1157 (C–N), 3194–2854 (C–H), 3302 (COOH); MS: m/z = 585.6 (M⁺).

2.3. Biological evaluation

2.3.1. Antibacterial activity assay

The newly synthesized compounds (4a-4n) were evaluated for antibacterial activities using agar well diffusion method (McFarland, 1907) and by minimum inhibitory concentration (MIC) method (Kumar et al., 2009). Nutrient agar media and King's B media were used for the biological assay as per the following composition: Nutrient agar media (NAM) made up of peptone 5 g, beef extract 3 g, NaCl 5 g, nutrient agar 2% and the final volume of media was adjusted to 1000 ml with double distilled water (pH 7.0). King's B media containing peptone 2%, glycerol 1%, KH₂PO₄ 0.15%, MgSO₄ 0.15%, agar 2% and the final volume of media was adjusted to 1000 ml with distilled water (pH 7.0). Synthesized compounds were screened for antibacterial activities against two Gram-positive bacteria i.e. Staphvlococcus auerus (NCDC 110) and Bacillus subtilis (NCDC 71) and two Gram-negative bacteria i.e. E. coli (NCDC 134) and P. aeruginosa (NCDC 105). The bacterial cultures were revived as per the protocol provided by the National Collection of Dairy Cultures (NCDC) Karnal, India. P. aeruginosa culture was maintained on King's B media while all other cultures were maintained on nutrient agar media. Suspension of each test organism was prepared to evaluate antibacterial activity of the synthetic compounds. All stock cultures were stored at 4 °C.

Each petri plate was prepared by pouring 40 ml of appropriate agar media. A fixed volume (100 μ l) of respective microorganism was spread on each petri plate with the help of a spreader. In each seeded agar plate, wells were bored using a borer of 6 mm diameter. Three concentrations (100, 50, and 10 μ g/ml) of each compound reconstituted in dimethyl sulphoxide (DMSO) were added to the wells of seeded plates. DMSO was used as a control for all the experiments. The plates were kept in laminar air flow for 15 min to allow

Compound	S. auerus (NCDC 110)			B. subtilis (NCDC 71)		E. coli (NCDC 134)			P. aeruginosa (NCDC 105)			
	10	50	100	10	50	100	10	50	100	10	50	100
4a	_	2.5	5.0	-	8.0	8.5	_	5.8	6.5	2.5	3.3	5.3
4b	-	5.0	6.0	-	-	-	-	-	-	3.0	3.1	4.5
4c	-	-	-	-	-	3.8	-	-	-	2.5	2.8	3.0
4d	-	4.3	5.2	3.8	6.8	8.0	-	2.7	6.5	2.5	3.0	3.5
4e	-	2.0	6.0	-	-	4.3	-	-	-	3.0	3.3	3.4
4f	-	-	4.3	-	4.3	5.8	-	-	4.5	3.0	3.5	3.7
4g	9.0	14.0	15.0	7.3	10.0	10.5	-	8.0	10.0	2.8	3.5	5.0
4h	4.3	7.5	10.0	6.5	10.0	11.0	10.3	14.8	15.0	2.8	6.8	7.1
4i	8.5	10.2	10.7	-	5.5	7.3	-	3.0	5.0	1.3	2.3	2.5
4j	11.3	12.8	15.0	7.5	9.0	10.3	7.8	11.0	13.3	3.3	3.8	5.0
4k	-	4.2	5.7	-	2.8	3.0	-	-	3.8	-	-	3.8
41	-	5.5	7.5	-	2.8	5.0	-	4.0	3.5	3.8	3.8	5.0
4m	-	2.7	5.0	-	3.8	4.5	-	-	-	1.5	3.3	4.0
4n	7.5	10.5	12.0	-	5.0	6.8	1.0	4.3	6.0	-	3.3	5.0
Norfloxacin	9.2	10.5	12.5	5.0	8.0	10.2	4.2	8.5	10.8	1.0	2.0	7.2
Ciprofloxacin	8.0	11.0	13.0	8.0	11.0	12.2	8.2	10.5	11.3	4.5	8.0	10.9
Gatifloxacin	8.0	11.0	11.3	6.5	10.2	11.5	6.0	9.7	9.8	2.7	4.2	4.7
Control	-	-	-	-	-	-	_	—	_	-	-	-

Table 2 Zone of inhibition in mm at 10, 50 and 100 $\mu g/ml$ concentrations.

Table 3 Minimum inhibitory concentration (MIC) in µg/ml against S. auerus, B. subtilis, E. coli, P. aeruginosa bacterial strains.

Compound	S. auerus (NCDC 110)	B. subtilis (NCDC 71)	E. coli (NCDC 134)	P. aeruginosa (NCDC 105)
4a	35	30	20	100
4b	05	120	140	120
4c	100	50	140	30
4d	40	15	05	30
4 e	20	35	100	20
4f	30	10	30	110
4g	35	150	05	50
4h	10	30	175	20
4i	30	40	20	80
4j	15	25	35	35
4k	80	70	80	120
41	05	15	20	35
4m	120	100	90	20
4n	25	55	05	20
Norfloxacin	10	05	70	15
Ciprofloxacin	50	20	25	60
Gatifloxacin	05	100	100	50
Control	-	-	-	-

diffusion of the compounds into the agar. The plates were incubated at 37 °C for 16 h and antibacterial activity was determined by measuring the diameter of inhibition zone. Each test was performed in triplicates and mean diameter of zone of inhibition was calculated. The results obtained were compared against three standard drugs, i.e. ciprofloxacin, norfloxacin, and gatifloxacin.

MIC of the newly synthesized compounds was determined using the method described by Kumar et al. (2009). A stock solution of 3 mg/ml of each compound was prepared in DMSO and further diluted to get a final concentration ranging from 200–0.05 μ g/ml. Optical density was measured at 600 nm using UV–visible spectrophotometer. The minimum concentration, where no microbial growth was observed is called as MIC of the compound.

3. Results and discussion

The synthetic route of desired compounds is presented in Scheme 1. The requisite 2-amino-6-substituted benzothiazoles (**2a–2e**) were prepared according to the method described by Stuckwisch (1949). Reaction between 2-amino-6-substituted benzothiazole, different fluoroquinolones and carbon disulfide in the presence of basic medium composed of sodium bicarbonate and N,N-dimethyl formamide, afforded the target compounds after a refluxing time of 10 h. The fluoroquinolone derivatives (**4a–4n**) were found in 58–72% yields. TLC analysis was done to confirm the purity of the compound. Analytical and spectral data (IR and ¹H NMR) of all the newly synthesized compounds were found in full agreement with the proposed structures. In the ¹H NMR spectra the signals of the respective proton of the compounds were verified on the basis of their chemical shifts, multiplicities. The spectra showed a characteristic singlet of one proton in DMSO- d_6 at δ 8.8–9.4 ppm corresponding to NH group of thiomide linkage, proton at the second position of quinolone ring showed a characteristic singlet at a shift at δ 8.6–8.9 ppm and a broad singlet at δ 14.7–15.3 ppm of COOH group. The IR spectra of compounds revealed C = O, C = C, stretching at approximately 1710, 1600 cm⁻¹, whereas in general C-O, O-H and C-H bands were revealed at nearby 1300, 3400, 2900 and 3000. It was found interesting that only two compounds among all were in lesser yield than 60% whereas all other compounds are in good yields. Compound 1-ethyl-6-fluoro-7-(4-(N-(6-fluoro-1.3-benzothiazol-2-vl)amino-1-thio-methyl) piperazin-1-yl)-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid was afforded in most effective yield of 72%. Melting range of various compounds of this series is found to be higher than 200 °C. Compound 4g showed the maximum melting temperature among all synthesized compounds which is 332-335 °C.

All the synthesized fluoroquinolone derivatives were screened for antibacterial activities against two Gram positive bacterial strains i.e. *S. auerus* (NCDC 110) and *Bacillus subtilis* (NCDC 71) and two Gram negative strains i.e. *E. coli* (NCDC 134) and *P. aeruginosa* (NCDC 105). The antibacterial activity was determined by measuring the diameter of the zone of inhibition and minimum inhibitory concentration (MIC). The results of zone of inhibition and MIC screening are summarized in Tables 2 and 3 respectively.

These novel derivatives demonstrated varying antibacterial activity (zone of inhibition) against different strains. Compound **4j** possessing bromo functionality at position-6 of benzothiazole nucleus, depicted significant zone of inhibition of 11.3, 12.8 and 15.0 mm at 10, 50 and 100 μ g/ml concentrations respectively against *S. auerus*. Compounds bearing N-cyclopropyl functionality i.e. **4g**, **4h**, **4i** and **4n** also found to possess significantly potent antibacterial activities against *S. auerus* and the zone of inhibition depicted by ciprofloxacin analogs **4g**, **4i** and **4j** was even better than the standard antibiotics ciprofloxacin, norfloxacin, and gatifloxacin when tested against *S. auerus*. While compound 1-cyclopropyl-6-fluoro-7-(4-(N-(6-fluoro-1,3-benzothiazol-2-yl)amino-1-thio-methyl)-3-methylpiperazin-1-yl)-8-methoxy-1,4-dihydro-4-oxo-quinoline-3-car-

boxylic acid showed moderate activity. Compounds 4g, substituted with the NO2 group at position-6 of benzothiazolyl moiety annulated with ciprofloxacin molecule, depicted zone of inhibition of 7.3 mm at concentration 10 µg/ml against Gram positive Bacillus subtilis bacterial strain exhibit even better activity than the standard drugs norfloxacin (5.0 mm) and gatifloxacin (6.5 mm). Compounds 4d, 4h and 4j exhibited good antibacterial activities against Bacillus subtilis while 4g, 4h and 4j showed moderate activity and the activities shown by 4h and 4j are significantly potent having a zone of inhibition of 10.3 and 7.8 mm respectively at concentration 10 µg/ml against the standard antibiotics norfloxacin (4.2 mm) and gatifloxacin (6.0 mm). Analogs 4h and 4j showed even better antibacterial activities against the standard antibiotics ciprofloxacin, norfloxacin and gatifloxacin when tested against E. coli and 1-cyclopropyl-6-fluoro-7-(4-(N-(6-nitro-1,3-benzothiazol-2-yl)amino-1-thio-methyl)piperazin-1-yl)-1,4-dihy-

dro-4-oxo-quinoline-3-carboxylic acid showed comparable activities at higher concentration (50 μ g/ml and 100 μ g/ml). Compounds **4b**, **4e**, **4f**, **4g**, **4h**, **4j**, **4l** and **4m** showed improved

antibacterial activities against the standard antibiotics norfloxacin and gatifloxacin when tested against *P. aeruginosa*.

When tested against S. auerus compounds having nitro substitution at position-6 of benzothiazole clubbed with norfloxacin (4b) and gatifloxacin (4l) showed MIC $05 \mu g/ml$, which is 10 times more potent as compared to the standard drug ciprofloxacin (MIC value 50 µg/ml). While all the norfloxacin and ciprofloxacin derivatives showed comparable activity. Compounds 4a, 4c, 4e, 4h, 4i and 4j showed significant MIC against Bacillus subtilis when compared with standards. Moreover, compounds 4d, 4f and 4l showed superior MIC (15, 10, 15 µg/ml respectively) against Bacillus subtilis than the standard antibiotics ciprofloxacin (MIC value 20 µg/ml) and gatifloxacin (MIC value 100 ug/ml). Analogs 4g, 4i, 4l and 4n showed better MIC against the standard antibiotics ciprofloxacin, norfloxacin and gatifloxacin when tested against E. coli. Compounds 4c, 4d, 4e, 4g, 4h, 4j, 4l, 4m and 4n showed comparable MIC against the standard antibiotics norfloxacin and gatifloxacin when tested against P. aeruginosa.

4. Conclusion

In conclusion, we have synthesized fourteen novel derivatives of three fluoroquinolone drugs i.e. norfloxacin, ciprofloxacin and gatifloxacin. These drugs have been linked to different 2-amino-6-substituted benzothiazoles via thiomide bridge linkage. The derivatives are characterized by physicochemical and spectral analyses such as ¹H NMR and IR. The spectral data obtained were in full agreement with the proposed structures. The *in vitro* evaluation of newly synthesized compounds revealed improved therapeutic effectiveness as compared to the parent drugs. Some derivatives showed more potent or equipotent antibacterial activities against different strains (*S. auerus, B. subtilis, E. coli, P. aeruginosa*). The experimental data of this investigation reveal that the synthesized novel derivatives of fluoroquinolones have remarkable antibacterial potential.

References

- Andriole, T.V., 1988. The Quinolones. Academic Press, New York, pp. 1–55.
- Chu, D.T.W., Fernandes, P.B., Claiborne, A.K., Pihuleac, E., Nordeen, C.W., Maleczka, R.E., Pernet, A.G., 1985. J. Med. Chem. 28, 1558–1564.
- Dinakaran, M., Senthilkumar, P., Yogeeswari, P., China, A., Nagaraja, V., Sriram, D., 2008. Bioorg. Med. Chem. 16, 3408–3418.
- Domagala, J.M., Heifetz, C.L., Hutt, M.P., Mich, T.F., Nichols, J.B., Solomon, M., Worth, D.F., 1988. J. Med. Chem. 31, 991–1001.
- El-Gazzar, A.B.A., Youssef, M.M., Youssef, A.M.S., Abu-Hashem, A.A., Badria, F.A., 2009. Eur. J. Med. Chem. 44, 609–624.
- Foroumadi, A., Emami, S., Hassanzadeh, A., Rajaee, M., Sokhanvar, K., Moshafi, M.H., Shafiee, A., 2005. Bioorg. Med. Chem. Lett. 15, 4488–4492.
- Foroumadi, A., Ghodsi, S., Emami, S., Najjari, S., Samadi, N., Faramarzi, M.A., Shirazid, L.B.F.H., Shafiee, A., 2006. Bioorg. Med. Chem. Lett. 16, 3499–3503.
- German, N., Wei, P., Kaatz, G.W., Kerns, R.J., 2008. Eur. J. Med. Chem. 43, 2453–2463.
- Graul, A., Rabasseda, X., Castaner, J., 1999. Drug Fut. 24, 1324-1331.
- Jayashree, B.S., Thomas, S., Nayak, Y., 2009. Med. Chem. Res. 19, 193–209.

- Jazayeri, S., Moshafi, M.H., Firoozpour, L., Emami, S., Rajabalian, S., Haddad, M., Pahlavanzadeh, F., Esnaashari, M., Shafiee, A., Foroumadi, A., 2009. Eur. J. Med. Chem. 44, 1205–1209.
- Kharb, R., Shaharyar, M., Sharma, P.C., 2011. Curr. Med. Chem. 18, 3265–3297.
- Kharb, R., Sharma, P.C., Shaharyar, M., 2011a. J. Enzyme Inhib. Med. Chem. 26, 1–21.
- Kharb, R., Sharma, P.C., Shaharyar, M., 2011b. Mini Rev. Med. Chem 11, 84–96.
- Kumar, R., Nair, R.R., Dhiman, S.S., Sharma, J., Prakash, O., 2009. Eur. J. Med. Chem. 44, 2260–2264.
- Lv, K., Sun, Y., Sun, L., Wei, Z., Guo, H., Wu, J., Liu, M., 2012. ChemMedChem. 7, 1230–1236.
- McFarland, J., 1907. J. Am. Med. Assoc. 14, 1176-1178.
- Senthilkumar, P., Dinakaran, M., Yogeeswari, P., Sriram, D., China, A., Nagaraja, V., 2009. Eur. J. Med. Chem. 44, 345–358.
- Sharma, P.C., Jain, S., 2008. Acta Pol. Pharm. Drug Res. 65, 551-556.
- Sharma, P.C., Jain, S., 2008. Acta Pharm. Sci. 50, 35-40.

- Sharma, P.C., Jain, A., Jain, S., 2009. Acta Pol. Pharm. Drug Res. 66, 587–604.
- Sharma, P.C., Jain, A., Jain, S., Pahwa, R., Shahar Yar, M., 2010. J. Enzyme Inhib. Med. Chem. 25, 577–589.
- Sharma, O.P., Sharma, P.C., Jain, S. 2011. In: Proceedings of the International Conference on Bioscience, Biochemistry and Bioinformatics, held at Singapore, February 26–28, pp. 1–5.
- Sharma, P.C., Kaur, G., Pahwa, R., Sharma, A., Rajak, H., 2011a. Curr. Med. Chem. 18, 4786–4812.
- Sharma, P.C., Kumar, R., Chaudhary, M., Sharma, A., Rajak, H., 2011b. J. Enzyme Inhib. Med. Chem. (Accepted Manuscript)
- Sharma, P.C., Jain, A., Shahar Yar, M., Pahwa, R., Singh, J., Goel, S., 2015. Arab. J. Chem. 8, 671–677.
- Stuckwisch, C.G., 1949. J. Am. Chem. Soc. 71, 3417.
- Winter, R.W., Kelly, J.X., Smilkstein, M.J., Dodean, R., Hinrichs, D., Riscoe, M.K., 2008. Exp. Parasitol. 118, 487–497.